title: Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide.
abstract: The CB1 cannabinoid receptor antagonist, N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (rimonabant; SR141716A), and oleoylethanolamide (OEA) are known to reduce food consumption, by, at least partially, a peripheral regulation of feeding. The effects of systemic SR141716A or OEA (5 mg/kg) administrations on food consumption in 24 h food-deprived and fed rats were investigated. In fasted rats, SR141716A and OEA produced an inhibition in food intake measurable the first 20 min following injection. The increase in ghrelin levels observed in the vehicle-injected rats was abolished in animals receiving OEA and significantly reduced with SR141716A. Neither OEA nor SR141716A modified glucagon-like peptide-1 (7-36) amide portal levels 20 min after the administration. In fed rats, plasma ghrelin levels of SR141716A- and OEA-treated rats were 35% lower as compared with those of the vehicle-injected rats. These results show an influence of cannabinoid agents on circulating ghrelin levels and suggest that their short-term action on appetite seems to be in accordance with the control of secretion of gastrointestinal orexigenic peptides, mainly expressed in the upper part of the gastrointestinal tract.
authors.affiliation: Unité de Pharmacocinétique, Métabolisme, Nutrition et Toxicologie, Ecole de Pharmacie, Université catholique de Louvain, Brussels, Belgium.
authors.forename: Patrice D
authors.initials: PD
authors.lastname: Cani
authors.forename: Maite Lasa
authors.initials: ML
authors.lastname: Montoya
authors.forename: Audrey M
authors.initials: AM
authors.lastname: Neyrinck
authors.forename: Nathalie M
authors.initials: NM
authors.lastname: Delzenne
authors.forename: Didier M
authors.initials: DM
authors.lastname: Lambert
mesh_terms: D000818:Animals; D001069:Appetite Regulation / Q000187:drug effects; D001786:Blood Glucose / Q000032:analysis; D015153:Blotting, Western / Q000379:methods; D002186:Cannabinoids / Q000037:antagonists & inhibitors*; D004435:Eating / Q000187:drug effects; D063388:Endocannabinoids; D054439:Ghrelin; D005934:Glucagon / Q000097:blood*; D052216:Glucagon-Like Peptide 1; D008297:Male; D009829:Oleic Acids / Q000494:pharmacology*; D010446:Peptide Fragments / Q000097:blood*; D036361:Peptide Hormones / Q000097:blood*; D010880:Piperidines / Q000494:pharmacology*; D011498:Protein Precursors / Q000097:blood*; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D011955:Receptors, Drug / Q000037:antagonists & inhibitors; D000077285:Rimonabant
chemical_list: D001786:Blood Glucose; D002186:Cannabinoids; D063388:Endocannabinoids; D054439:Ghrelin; D009829:Oleic Acids; D010446:Peptide Fragments; D036361:Peptide Hormones; D010880:Piperidines; D011498:Protein Precursors; D011720:Pyrazoles; D011955:Receptors, Drug; C488250:oleoylethanolamide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077285:Rimonabant